Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Fosamax by Quarter
Fosamax (alendronate, legacy pre-Organon spin-off) — U.S. sales ($M) ($M)
Merck Fosamax: $1M in Q4 2018, down 200.0% from a year earlier. No newer figure appears in the documents we track.
Where the Q4 2018 figure comes from
“|| Fosamax | 50 | 62 | -18 | 1 | (1 | ) | * | 49 | 62 | -21”
Source: Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Fosamax (alendronate, legacy pre-Organon spin-off) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2018 | Dec 31, 2018 | 1 | -200.0% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| Q3 2018 | Sep 30, 2018 | 2 | -50.0% | Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 3 | +50.0% | Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗ |
| Q1 2018 | Mar 31, 2018 | -2 | -300.0% | Form 8-K (a18-12417_1ex99d1.htm, filed 2018-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | -1 | -150.0% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| Q3 2017 | Sep 30, 2017 | 4 | – | Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗ |
| Q2 2017 | Jun 30, 2017 | 2 | – | Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗ |
| Q1 2017 | Mar 31, 2017 | 1 | – | Form 8-K (a18-12417_1ex99d1.htm, filed 2018-05-01) ↗ |
| Q4 2016 | Dec 31, 2016 | 2 | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Breakdown
What makes up fosamax
Cite this data
StockData. (2026). Merck Fosamax ($M), quarterly Q4 2016–Q4 2018 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-fosamax-us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.